Helix Mainz GmbH & Co. KG

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis (2026) Kind B, Pham C, Heinrich L, Honstein T, Heratizadeh A, Harder I, Stölzl D, et al. Journal article Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry (2026) Traidl S, Cornelius A, Heinrich L, Siegels D, Zacharias H, Heratizadeh A, Honstein T, et al. Journal article Patient treatment needs in atopic dermatitis: A real-world cohort study (2026) Ludemann K, Traidl S, Cornelius A, Naim J, Heratizadeh A, Honstein T, Kind B, et al. Journal article Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany (2025) Heinrich L, Birkner T, Abraham S, Gerdes S, Honstein T, Müller S, Augustin M, et al. Journal article Obesity is linked to disease severity in moderate to severe atopic dermatitis—Data from the prospective observational TREATgermany registry (2024) Traidl S, Hollstein MM, Kroeger N, Fischer S, Heratizadeh A, Heinrich L, Kind B, et al. Journal article Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry (2024) Traidl S, Heinrich L, Siegels D, Heratizadeh A, Kind B, Haufe E, Abraham S, et al. Journal article Juckreiz, Schlafstörungen, depressive Symptome, Fatigue und Einschränkungen der Arbeitsproduktivität bei Patienten mit moderater bis schwerer atopischer Dermatitis: Daten aus dem TREATgermany-Register (2023) Birkner T, Siegels D, Heinrich L, Haufe E, Abraham S, Heratizadeh A, Harder I, et al. Journal article Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany (2023) Weisshaar E, Bentz P, Haufe E, Heinrich L, Apfelbacher C, Heratizadeh A, Abraham S, et al. Journal article Itch, sleep loss, depressive symptoms, fatigue, and productivity loss in patients with moderate-to-severe atopic dermatitis: Analyses of TREATgermany registry data (2023) Birkner T, Siegels D, Heinrich L, Haufe E, Abraham S, Heratizadeh A, Harder I, et al. Journal article Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis (2023) Hartmann J, Moitinho-Silva L, Sander N, Harder I, Häsler R, Rodriguez E, Haufe E, et al. Journal article